Developing therapies to treat C9orf72 ALS/FTD
About Us
Corsalex’s mission is to identify, fund, and develop promising projects to treat C9orf72 ALS/FTD.
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating adult-onset neurodegenerative diseases. Genetic analysis has revealed the hexanucleotide repeat expansion (HRE) disorder C9orf72 as the most common cause of familial ALS/FTD (C9-ALS/FTD).
Corsalex is a joint venture between KCK and Panorama Research. Led by Dr. James Larrick, a biomedical entrepreneur with an international reputation and over 30-year career in biotechnology, and backed by KCK, the Company hopes to spur innovation and advance meaningful interventions for this devastating disease.
Corsalex Model
License promising technologies.
Corsalex is actively looking to in-license promising technologies to advance into the clinic and through approval. We focus on disease modifying therapies that have a strong scientific rationale.
Fund early-stage research.
Whether it is early work to better understand the pathology of c9orf72 ALS/FTD, or translational work to bridge the gap between early findings and a drug candidate, Corsalex seeks to fund work in academic labs that can advance our understanding and treatment of this disease.
Partner with industry.
The landscape for treating CNS diseases is changing rapidly. To capitalize on these exciting developments, Corsalex is looking for collaborations with industry parters in a way that can spur c9-specific therapies.
Work with patient advocacy groups.
Our ultimate goal is to help patients and families with this devastating disease. To that end, we seek to partner with patient advocacy groups to help improve patients’ lives.
We would love to hear from you.
Whether you’re a potential partner in academia, industry, or the patient community, please reach out to us. Contact us via our contact form or email address below.
info@corsalex.com
ADDRESS
20400 Stevens Creek Boulevard, Suite 800, Cupertino, CA 95014.
Contact Form